The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index; 21 of the 52 sources its claims cite were checked for support.
Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients
Open accessAbstract
BACKGROUND: High-grade serous ovarian cancer (HGSOC) has poor survival rates due to a combination of diagnosis at advanced stage and disease recurrence as a result of chemotherapy resistance. In BRCA1 (Breast Cancer gene 1) - or BRCA2-wild type (BRCAwt) HGSOC patients, resistance and progressive disease occur earlier and more often than in mutated BRCA. Identification of biomarkers helpful in predicting response to first-line chemotherapy is a challenge to improve BRCAwt HGSOC management. METHODS: To identify a gene signature that can predict response to first-line chemotherapy, pre-treatment tumor biopsies from a restricted cohort of BRCAwt HGSOC patients were profiled by RNA sequencing (RNA-Seq) technology. Patients were sub-grouped according to platinum-free interval (PFI), into sensitive (PFI > 12 months) and resistant (PFI < 6 months). The gene panel identified by RNA-seq analysis was then tested by high-throughput quantitative real-time PCR (HT RT-qPCR) in a validation cohort, and statistical/bioinformatic methods were used to identify eligible markers and to explore the relevant pathway/gene network enrichments of the identified gene set. Finally, a panel of primary HGSOC cell lines was exploited to uncover cell-autonomous mechanisms of resistance. RESULTS: RNA-seq identified a 42-gene panel discriminating sensitive and resistant BRCAwt HGSOC patients and pathway analysis pointed to the immune system as a possible driver of chemotherapy response. From the extended cohort analysis of the 42 DEGs (differentially expressed genes), a statistical approach combined with the random forest classifier model generated a ten-gene signature predictive of response to first-line chemotherapy. The ten-gene signature included: CKB (Creatine kinase B), CTNNBL1 (Catenin, beta like 1), GNG11 (G protein subunit gamma 11), IGFBP7 (Insulin-like growth factor-binding protein 7), PLCG2 (Phospholipase C, gamma 2), RNF24 (Ring finger protein 24), SLC15A3 (Solute carrier family 15 member 3), TSPAN31 (Tetraspanin 31), TTI1 (TELO2 interacting protein 1) and UQCC1 (Ubiquinol-cytochrome c reductase complex assembly factor). Cytotoxicity assays, combined with gene-expression analysis in primary HGSOC cell lines, allowed to define CTNNBL1, RNF24, and TTI1 as cell-autonomous contributors to tumor resistance. CONCLUSIONS: Using machine-learning techniques we have identified a gene signature that could predict response to first-line chemotherapy in BRCAwt HGSOC patients, providing a useful tool towards personalized treatment modalities.
Overview
CoChat Summary
## TL;DR
This retrospective study in BRCA-wild-type HGSOC patients identified a 10-gene expression signature that predicted response to first-line platinum-based chemotherapy. The Random Forest model based on this signature reportedly achieved about 93% accuracy and 94% precision in the validation cohort.
## Key findings
- In the discovery cohort, RNA-seq measured 10,807 expressed genes and identified 258 differentially expressed genes (DEGs) at adjusted P < 0.05 and |log2FC| > 1; with stricter filtering (adjusted P < 0.005 and |log2FC| > 1), 42 DEGs were retained.
- KEGG pathway analysis of the 42 DEGs found 4 significantly enriched pathways: Fc Epsilon RI signaling (combined score 184.64; padj 0.027), Inositol phosphate metabolism (166.85; 0.027), Phosphatidylinositol signaling system (110.64; 0.033), and Chemokine signaling pathway (80.53; 0.027).
- In the validation cohort (25 sensitive, 19 resistant), HT RT-qPCR reduced the panel to 10 genes associated with chemotherapy response: 4 downregulated (GNG11, IGFBP7, PLCG2, SLC15A3) and 6 upregulated (CKB, CTNNBL1, RNF24, TSPAN31, TTI1, UQCC1).
- The Random Forest classifier using the 10-gene signature achieved about 93% classification accuracy and 94% precision; in primary HGSOC cell lines, CTNNBL1, RNF24, and TTI1 showed the same resistance-related trend as in patient tumors.
## Methods
- Retrospective study of 44 BRCAwt HGSOC women treated at a single center (2014–2018); discovery cohort was 14 patients (7 sensitive, 7 resistant) and validation cohort was 44 patients total with 25 sensitive and 19 resistant in the qPCR phase.
- Pretreatment frozen tumor biopsies were profiled by RNA-seq in the discovery cohort, then the 42-gene panel was tested by HT RT-qPCR in the validation cohort; patients were classified as sensitive (PFI > 12 months) or resistant (PFI < 6 months).
- Main analyses included differential expression testing, KEGG/ORA pathway analysis, GeneMANIA/cBioPortal network analyses, correlation between RNA-seq and qPCR, Wilcoxon testing, and a 4-fold cross-validation Random Forest classifier.
## Limitations
- The paper states that the study was retrospective, which makes it susceptible to bias.
- The paper states that sample size was not large enough to detect definitive associations between biomarker expression and response to therapy.
- Evident from the text: the study was conducted at a single tertiary-care center and the signature still needs prospective validation before clinical use.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
15 Valid · 2 Not valid · 23 Not checked · 57 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Our results confirm the low translational relevance of established cancer cell lines for the identification of clinical anti-cancer drug resistance [38].”
§ Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients > Results > Epithelial markers of sensitivity to chemotherapy
What the sources say
- Supportedcites [38] Gillet JP, Calcagno AM, Varma S, Marino M, Green LJ, Vora MI, et al. Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci U S A. 2011;108:18708–13. source
The Abstract reports no correlation between clinical samples and established cancer cell lines in their multidrug-resistance gene expression profiles. The section ‘Heterogeneity Among the Cell Lines Within Tumor Types of the NCI-60’ cautions against directly applying cell-line findings on clinical drug resistance to patients. The cited paper therefore supports the attributed point about limited translational relevance; ‘our results confirm’ is the citing authors’ own conclusion. (LLM, conf=0.92)
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These findings are in line with recent evidences indicating that chemoresistance in HGSOC stems from complex, and not fully understood, mechanisms linked to pre-existing gene expression intrinsic within the chemotherapy-naive tumor cells or the immediate microenvironment (revised in 6, [39]).”
§ Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients > Discussion
What the sources say
- Not checked — no full text of the sourcecites [6] Marchetti C, De Felice F, Romito A, Iacobelli V, Sassu CM, Corrado G, et al. Chemotherapy resistance in epithelial ovarian cancer: mechanisms and emerging treatments. Semin Cancer Biol. 2021;77:144-66. source
- Partly supportedcites [39] Yang Y, Yang Y, Yang J, Zhao X, Wei X. Tumor microenvironment in ovarian Cancer: function and therapeutic strategy. Front Cell Dev Biol. 2020;8:758. sourceExperimental — accuracy not yet measured
The review’s “Treatment Impact and Response Prediction in Ovarian Cancer TME” section (page unavailable) links recurrence to chemotherapy-resistant cancer stem cells and reports gene-expression and microenvironmental differences between treatment-naive and recurrent ovarian cancer. It does not establish that pre-existing gene expression in chemotherapy-naive HGSOC tumor cells or their immediate microenvironment gives rise to chemoresistance; the differences it describes were observed after treatment. (LLM, conf=0.82)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“RNA-seq identified a 42-gene panel discriminating sensitive and resistant BRCAwt HGSOC patients”
- Also stated in: § Study population · hedged
“This analysis allowed the identification of a restricted panel of 42 DEGs that could discriminate chemotherapy-sensitive from -resistant patients.”
§ Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients > Abstract > Results
plainstates an associationn = 14- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Also stated in: § Study population · hedged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The random forest classification model based on the ten-gene signature accurately differentiated S and R patients.”
§ Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients > Results > Validation of RNA-seq data by HT RT-qPCR
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The final gene panel included 4 downregulated (i.e. GNG11, IGFBP7, PLCG2 and SLC15A3) and 6 upregulated (i.e. CKB, CTNNBL1, RNF24, TSPAN31, TTI1 and UQCC1) genes (Table 2).”
- Also stated in: § Discussion · plain
“The signature includes downregulated (i.e. GNG11, IGFBP7, PLCG2, and SLC15A3) and upregulated (i.e. CKB, CTNNBL1, RNF24, TSPAN31, TTI1 and UQCC1) genes.”
- Also stated in: § Discussion · hedged
“Consistent with a role of the immune system in driving chemosensitivity are also our findings showing a downregulation of SLC15A3 in R vs S patients.”
§ Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients > Results > Validation of RNA-seq data by HT RT-qPCR
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Discussion · plain
37 more claims
Create a free account to see all 97 claims and to verify the 5 references still open.
- Probably not a substantial claim. 48
- It may state two separate claims as one. 27
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699 · cited 1×
“Nearly 314,000 women were estimated to have been diagnosed with ovarian cancer and 207,000 to have died from disease in 2020, with rates varying across the world [1].”
BackgroundModerated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106 · cited 1×
“The DEseq2 algorithm [23] was then used to determine DEGs at a significance threshold of Benjamini-Hochberg (BH) adjusted P value < 0.”
Wickham, H. (2016) · Use R! · doi:10.1007/978-3-319-24277-4 · Cited by 33,115
Vandesompele, J., De Preter, K., Pattyn, F., Poppe, B., Van Roy, N., De Paepe, A., & Speleman, F. (2002) · Genome Biology · doi:10.1186/gb-2002-3-7-research0034 · Cited by 20,038 · cited 1×
“The geometric mean of RPL13A, RPL4 and GAPDH was taken as reference genes, following GeNorm and Normfinder algorithm [18, 19].”
MethodNew Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660 · cited 1×
“Response to chemotherapy and progression were defined according to Response Evaluation Criteria in Solid Tumors (RECIST) and Gynecologic Cancer Intergroup (GCIG) criteria [10, 11].”
MethodIntegrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Andersen, C. L., Jensen, J. L., & Ørntoft, T. F. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0496 · Cited by 7,127 · cited 1×
“The geometric mean of RPL13A, RPL4 and GAPDH was taken as reference genes, following GeNorm and Normfinder algorithm [18, 19].”
Method
Research works printed but not linked: 3
- Leek JT, Johnson WE, Parker HS, Fertig EJ, Jaffe AE, Zhang Y, et al. Sva: surrogate variable analysis. R package version 3.40.0; 2021.
- Liaw A, Wiener M. Classification and regression by randomForest. R News. 2002;2:18–22.
- Slawski M, Boulesteix A, Bernau C (2021). CMA: synthesis of microarray-based classification. R package version 1.50.0.
Cited by
Current Status and Prospects of Clinical Treatment of Osteosarcoma
Jiang, Z.-Y., Liu, J., Wang, X., Ma, Y., & Fu, D. (2022) · Technology in Cancer Research & Treatment · doi:10.1177/15330338221124696 · Cited by 87
Molecular Management of High-Grade Serous Ovarian Carcinoma
Punzón-Jiménez, P., Lago, V., Domingo, S., Simón, C., & Mas, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213777 · Cited by 51
“identified a 10-gene signature (including genes such as CTNNBL1, CKB, GNG11, IGFBP7, and PLCG2) for classifying wild-type BRCA HGSOC patients into sensitiveand resistant-to-therapy groups [92].”
BackgroundCesari, E., Ciucci, A., Pieraccioli, M., Caggiano, C., Nero, C., Bonvissuto, D., Sillano, F., Buttarelli, M., Piermattei, A., Loverro, M., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02682-5 · Cited by 53
Self-citationCiucci, A., Buttarelli, M., Fagotti, A., Scambia, G., & Gallo, D. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04395-y · Cited by 51
Self-citationMulti-Omics Data Analysis Identifies Prognostic Biomarkers across Cancers
Karaman, E. D., & Işık, Z. (2023) · Medical Sciences · doi:10.3390/medsci11030044 · Cited by 36
“[52] generated a ten-gene signature, including the downregulated GNG11 gene, that predicts response to first-line chemotherapy in high-grade serous ovarian cancer patients.”
Background
Metadata
- Authors
- Buttarelli, M., Ciucci, A., Palluzzi, F., Raspaglio, G., Marchetti, C., Perrone, E., Minucci, A., Giacò, L., Fagotti, A., Scambia, G., & Gallo, D.
- Affiliations
- Università Cattolica del Sacro Cuore (IT)
- Agostino Gemelli University Polyclinic (IT)
- Corresponding author
- Gallo, Daniela
- ORCID
- Venue
- Journal of Experimental & Clinical Cancer Research
- Published
- 2022-02-04
- Volume
- 41
- Issue
- 1
- Pages
- 50-50
- ISSN
- 0392-9078 (ISSN-L)
- 1756-9966
- PMC
- PMC8815250
- OpenAlex
- W4210641711
- Semantic Scholar
- 949e7940be890966ef51d8f9f8799930479e4aea
- Cited by
- 32
- References
- 74
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 9 · 2023: 7 · 2022: 5
- FWCI
- 6.10
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Journal of Experimental & Clinical Cancer Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- PubliCatt (Università Cattolica del Sacro Cuore) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- high-grade serous ovarian cancer, BRCA wild-type, chemotherapy response prediction, gene expression signatures, platinum-free interval, chemoresistance, predictive biomarkers, immune response, creatine kinase B, PLCγ2, IGFBP7
- MeSH terms
- Female, Humans, Ovarian Neoplasms, Retrospective Studies, Survival Analysis, BRCA1 Protein, Gene Expression Profiling, Neoplasm Grading
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients. https://app.cochat.ai/papers/10.1186/s13046-022-02265-w
- The paper
- Buttarelli, M., Ciucci, A., Palluzzi, F., Raspaglio, G., Marchetti, C., Perrone, E., Minucci, A., Giacò, L., Fagotti, A., Scambia, G., & Gallo, D. (2022). Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-022-02265-w
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.